Currently sales, net profit are on the -ve side of the axis.
Even if they get success with all the mentioned trials and go in production.
It can increase sell /revenue. But will it make enough profit as much as retail investors are expecting is yet to come out.
So far they have run the business badly.
Dilution , promoter sell offs in last 3 quarters.
Deliverables: Their team is going to deliver the solution for the Pneumonia problem.
Marketing and sales deliverable is yet to be proven.
We need to watch out the business post all the approvals.
Risk is huge here even after the success of trials.
Based on technical deliverables people are taking huge position.
Sales validation is yet to happen.
| Subscribe To Our Free Newsletter |
